Gonorrhoea Summary

Pathogen

  • Neisseria gonorrhoeae
  • Gram-negative diplococcus
  • Mucous membrane transmission
  • Direct inoculation required

Male Symptoms

  • Urethral discharge (80%)
  • Dysuria (50%)
  • Symptoms in 2-5 days
  • Usually symptomatic

Female Symptoms

  • Asymptomatic in 50%
  • Vaginal discharge
  • Lower abdominal pain
  • Dysuria

Diagnosis

  • NAAT testing first-line
  • Culture for susceptibility
  • Refer to GUM clinic
  • Screen for other STIs

First-line Treatment

  • Ceftriaxone 1g IM
  • Single dose
  • Test of cure required
  • Partner notification

Complications

  • PID in women (up to 33%)
  • Epididymitis in men
  • Infertility risk
  • Disseminated infection

Gonorrhoea Infection

A sexually transmitted infection caused by Neisseria gonorrhoeae - transmitted by direct inoculation between mucous membranes

Pathophysiology & Classification

Causative Agent

Neisseria gonorrhoeae - Gram-negative diplococcus bacterium transmitted through direct inoculation of secretions between mucous membranes during sexual contact.

Uncomplicated Gonorrhoea

  • Localised infection
  • Affects mucous membranes:
  • - Urethra
  • - Endocervix
  • - Rectum
  • - Pharynx
  • - Conjunctiva
  • Most common in ages 15-24

Disseminated Gonorrhoea

  • Uncommon but serious
  • Systemic spread
  • Petechial/pustular skin lesions
  • Asymmetrical arthralgia
  • Tenosynovitis
  • Septic arthritis
  • Rare: meningitis, endocarditis

Epidemiology

Highest incidence: Young adults aged 15-24 years. Increasing antimicrobial resistance globally makes appropriate testing and treatment crucial.

Clinical Features

Presentation in Men

Genital Infection

  • Usually symptomatic
  • Mucopurulent/purulent urethral discharge (>80%)
  • Dysuria (>50%)
  • Symptoms appear within 2-5 days
  • No effect on urinary frequency/urgency

Extra-genital Sites

  • Rectal infection:
  • - Usually asymptomatic
  • - Anal discharge (12%)
  • - Acute proctitis
  • - Perianal pain (7%)
  • - Tenesmus, rectal bleeding

Other Manifestations

  • Pharyngeal infection:
  • - Asymptomatic (>90%)
  • - Tonsillitis/pharyngitis
  • Complications:
  • - Prostatitis
  • - Epididymitis
  • - Orchitis

Presentation in Women

Urogenital Symptoms

  • Asymptomatic in up to 50%
  • Symptoms develop within 10 days
  • Increased/altered vaginal discharge (50%)
  • Lower abdominal pain (25%)
  • Dysuria (12%)
  • Intermenstrual bleeding (rare)
  • Dyspareunia

Examination Findings

  • Often normal examination
  • Mucopurulent endocervical discharge (<50%)
  • Easily induced endocervical bleeding
  • Pelvic/abdominal tenderness (<5%)
  • Pharyngeal infection:
  • - Asymptomatic (90%)
  • - Tonsillitis/pharyngitis

Diagnosis

Referral Recommendation

Ideally refer all suspected cases to genito-urinary medicine (GUM) clinic or specialist sexual health service for confirmation and management.

Testing Strategy

Nucleic Acid Amplification Test (NAAT)

  • First-line diagnostic test
  • Women: Vulvovaginal swab (self-taken acceptable)
  • Men: First-pass urine specimen
  • Follow local protocols if GUM referral declined

Culture & Sensitivity

  • Essential for all NAAT-positive cases
  • Required before antibiotic prescription
  • Tests antimicrobial susceptibility
  • Identifies resistant strains
  • Guides appropriate treatment

Site-Specific Testing

  • Pharyngeal and rectal sites should be tested in individuals reporting relevant sexual practices
  • Extra-genital sites may be asymptomatic but still infectious
  • Multi-site testing increases detection rates

Management

First-line Treatment Protocol

Known Susceptibility

  • Ciprofloxacin 500mg
  • Oral single dose
  • Only if susceptibility confirmed

Unknown Susceptibility

  • Ceftriaxone 1g IM
  • Single intramuscular injection
  • Current first-line recommendation

Alternative Regimens

For Allergies/Contraindications

  • Option 1: Gentamicin 240mg IM single dose PLUS Azithromycin 2g oral single dose
  • Option 2: Cefixime 400mg oral single dose PLUS Azithromycin 2g oral single dose
  • Monitor local resistance patterns regularly
  • Consider needle phobia, allergies, other contraindications

Essential Adjuncts to Treatment

Intervention Details
Sexual Abstinence Until patient and all partners complete treatment
STI Screening Screen for other STIs including HIV
Partner Notification Encourage patient-led notification of all partners
Health Education Provide appropriate information and advice
Test of Cure Required for all treated cases at 1-week follow-up

Special Populations

  • Children & Young People: Consider possibility of sexual abuse
  • Pregnancy: Requires specialist management
  • HIV Co-infection: Coordinate care with HIV team

Complications

Complications in Men

Local Complications

  • Epididymitis
  • Orchitis
  • Prostatitis
  • Urethral stricture
  • Infertility

Glandular Infections

  • Infection of Mullerian glands
  • Infection of Cowper glands
  • Local abscess formation
  • Chronic pain syndromes

Complications in Women

Pelvic Inflammatory Disease

  • Occurs in up to 33% of women
  • Chronic pelvic pain
  • Tubal infertility
  • Ectopic pregnancy risk
  • Long-term reproductive morbidity

Other Complications

  • Peritoneal spread
  • Perihepatic abscesses (Fitz-Hugh-Curtis)
  • Pregnancy complications
  • Congenital infections

Systemic Complications

Disseminated Gonococcal Infection

  • Uncommon but serious
  • Petechial or pustular skin lesions
  • Asymmetrical arthralgia
  • Arthritis and tenosynovitis
  • Rare: meningitis, endocarditis
  • Requires hospital admission and IV antibiotics

Pregnancy Implications

  • Associated with miscarriage
  • Increased risk of fetal loss
  • Congenital infections in newborn
  • Ophthalmia neonatorum risk
  • Requires prompt treatment and follow-up

Prevention & Public Health

Primary Prevention

  • Consistent condom use
  • Sexual health education
  • Regular STI screening
  • Partner communication
  • Reducing number of sexual partners

Secondary Prevention

  • Prompt diagnosis and treatment
  • Effective partner notification
  • Test of cure verification
  • Re-screening after treatment
  • Contact tracing

Antimicrobial Stewardship

  • Culture before treatment when possible
  • Follow current guidelines
  • Monitor resistance patterns
  • Appropriate test of cure
  • Report treatment failures

Public Health Responsibilities

  • Report cases to public health authorities
  • Participate in surveillance programs
  • Educate about rising antimicrobial resistance
  • Support sexual health services
  • Promote accessible testing